Policy & Regulation
Auditus signs contract with Oblato
12 February 2020 -

Auditus LLC, the pharmaceutical partner of Hough Ear Institute and a wholly owned subsidiary of Otologic Pharmaceutics Inc, has signed a contract with Oblato Inc, it was reported on Tuesday.

Oblato assumes exclusive rights to a drug called NHPN-1010 to advance clinical research intended at preserving and possibly restoring hearing.

Under the contract, Oblato is likely to start a phase two clinical trial to assess the potential of the drug to prevent and treat hearing loss. Follow-up studies are likely to test efficacy for treating tinnitus and improving ability to understand speech in the presence of background noise.

At this time, no drug treatment or cure exists for noise induced hearing loss (NIHL) or tinnitus.